Skip to main content
. Author manuscript; available in PMC: 2009 Jul 8.
Published in final edited form as: Blood. 2009 Jan 26;113(18):4331–4340. doi: 10.1182/blood-2008-09-178350

Figure 3. Prognostic relevance of Aurora-A expression for two independent groups of patients treated with high-dose therapy and autologous stem cell transplantation.

Figure 3

Shown are (A) event-free (EFS) and (B) overall survival (OAS) in our cohort of patients (left side) and the Arkansas-group (right side) for absence (black curve) vs. presence (grey curve) of Aurora-A expression in CD138-purified myeloma cells. Presence of Aurora-A expression in myeloma cells is an adverse prognostic factor in terms of EFS and OAS in both groups.